American Journal of Medicine, internal medicine, medicine, health, healthy lifestyles, cancer, heart disease, drugs

Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement

Patients' educational program. *Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home.

Patients’ educational program. *Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home.

 

Mobile Health technology for the management of patients with atrial fibrillation is unknown.

Methods

The simple mobile AF (mAF) App was designed to incorporate clinical decision-support tools (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65–74 years, Sex category], HAS-BLED [Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly], SAMe-TT2R2 [Sex, Age <60 years, Medical history, Treatment, Tobacco use, Race] scores), educational materials, and patient involvement strategies with self-care protocols and structured follow-up. Patients with atrial fibrillation were randomized into 2 groups (mAF App vs usual care) in a cluster randomized design pilot study. Patients’ knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evaluated at baseline, 1 month, and 3 months. Usability, feasibility, and acceptability of the mAF App were assessed at 1 month.

Results

A total of 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5% were male; mean follow-up, 69 days), and 96 patients were randomized to usual care (mean age, 70.9 years; 55.2% were male; mean follow-up, 95 days). More than 90% of patients reported that the mAF App was easy, user-friendly, helpful, and associated with significant improvements in knowledge compared with the usual care arm (P values for trend <.05). Drug adherence and anticoagulant satisfaction were significantly better with the mAF App versus usual care (all P < .05). Quality of life scores were significantly increased in the mAF App arm versus usual care, with anxiety and depression reduced (all P < .05).

Conclusions

The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support, education, and patient-involvement strategies, significantly improved knowledge, drug adherence, quality of life, and anticoagulation satisfaction.

To read this article in its entirety please visit our website.

-Yutao Guo, MD, PhD, Yundai Chen, MD, PhD, Deirdre A. Lane, PhD, Lihong Liu, MD, Yutang Wang, MD, PhD, Gregory Y.H. Lip, MD

This article originally appeared in the December 2017 issue of The American Journal of Medicine.

To watch a video related to this article from our Editor in Chief Dr. Joseph Alpert, follow this link.

Comments are closed.

UA-42320404-1